Ranjana Advani, MD
Medical Oncology · Stanford, CANPI 1639225121
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $88,756 of the $112,980 with a category attached, or 78.6%. 18 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 27.1% of the total. Reporting peaked in 2021 at $23,331 and has fallen 54.8% since, to $10,537 in 2025.
Across 75 payments — averaging $1506.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$31K
- ADC Therapeutics America, Inc.$12K
- Genentech, Inc.$10K
- Merck$9K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Bristol Myers Squibb$6K
- plus $37K from 12 others
Across 375 payments — averaging $20,019 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.1M
- Genentech, Inc.$736K
- Seagen Inc.$713K
- Janssen Research & Development, LLC$623K
- Regeneron$359K
- Takeda Pharmaceuticals U.S.A., Inc.$283K
- plus $652K from 12 others
What the payments were for
- Consulting fees$88,75679%
- Speaking & faculty fees$14,62313%
- Travel & lodging$8,2437%
- Food & beverage$1,3491%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 18 | $30,603 |
| ADC Therapeutics America, Inc. | 5 | $11,900 |
| Genentech, Inc. | 10 | $10,171 |
| Merck | 6 | $9,180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $8,627 |
| Bristol Myers Squibb | 4 | $5,555 |
| Pfizer | 4 | $5,424 |
| Sanofi-aventis U.S. LLC | 7 | $5,200 |
| Incyte Corporation | 3 | $4,305 |
| Beigene Switzerland GmbH | 3 | $4,280 |
| Seagen Inc. | 5 | $2,966 |
| Gilead | 1 | $2,850 |
| Genmab U.S., Inc. | 2 | $2,663 |
| Daiichi Sankyo Inc. | 1 | $2,344 |
| Epizyme, Inc. | 1 | $2,050 |
| Karyopharm Therapeutics Inc. | 1 | $1,938 |
| Beigene USA, Inc. | 1 | $1,625 |
| Sanofi US Services Inc. | 1 | $1,300 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,980 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.